Sep 05, 2017 12:30 pm UTC| Business
WARREN, N.J., Sept. 05, 2017 -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced positive top line data from a Phase 2 clinical trial evaluating INOpulse® in...
Aptose Biosciences to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
Sep 05, 2017 12:30 pm UTC| Business
SAN DIEGO and TORONTO, Sept. 05, 2017 -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today...
Yield10 Bioscience to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
Sep 05, 2017 12:30 pm UTC| Business
WOBURN, Mass., Sept. 05, 2017 -- Yield10 Bioscience, Inc. (NASDAQ:YTEN), a Company focused on developing new technologies to achieve step-change improvements in crop yield to enhance global food security, today...
Why Zero is Celebrated at Northfield Mount Hermon School
Sep 05, 2017 12:30 pm UTC| Business
MOUNT HERMON, Mass., Sept. 05, 2017 -- Northfield Mount Hermon (NMH), a coed boarding high school in Western Massachusetts dedicated to education for the head, heart, and hand, today announced it has entered into new...
Gladstone Land Acquires Vineyard in California for $5.4 Million
Sep 05, 2017 12:30 pm UTC| Business
MCLEAN, Va., Sept. 05, 2017 -- Gladstone Land Corporation (NASDAQ:LAND) (“Gladstone Land” or the “Company”) announced that it acquired a 361-acre vineyard in Santa Barbara County, California, for approximately $5.4...
Galectin Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
Sep 05, 2017 12:30 pm UTC| Business
NORCROSS, Ga., Sept. 05, 2017 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will present at the Rodman Renshaw 19th...
ChemoCentryx to Present at Three Upcoming Investor Conferences
Sep 05, 2017 12:30 pm UTC| Business
MOUNTAIN VIEW, Calif., Sept. 05, 2017 -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that Thomas...